Elicio Therapeutics, Inc.

Elicio Therapeutics is a clinical-stage biotechnology company that develops novel cancer immunotherapies, specifically targeting oncogenic drivers such as mutant Kirsten rat sarcoma viral oncogene homolog (mKRAS) in pancreatic, colorectal, and lung cancers. The company utilizes its proprietary Amphiphile platform, which leverages albumin hitchhiking to deliver therapeutic payloads directly to lymph nodes to generate robust, cancer-specific T cell responses. Its clinical pipeline is led by ELI-002, an off-the-shelf lymph-node-targeted peptide immunotherapy evaluated in Phase 1 and Phase 2 trials for mKRAS-driven solid tumors. Its preclinical programs include ELI-007 and ELI-008, targeting mutant BRAF and TP53 driver mutations, respectively, alongside potential platform applications for cellular therapies and auto-immune conditions.

The company engages in clinical and preclinical development through collaborative relationships with academic and medical institutions, including a worldwide patent licensing agreement with the Massachusetts Institute of Technology. The provided text details ongoing multicenter clinical evaluations and partnership opportunities across its immunotherapy pipeline, though it does not state specific facility numbers, operational countries, or the location of its corporate headquarters.

Summary of the business section of Elicio Therapeutics's latest annual report, written by StockData.

“As of December 31, 2025, we had 33 employees, all of whom were full-time, 9 of whom have Ph.D.”